Table 7 Adverse effects according to the value of the initial and maximal trough concentration (Cmin)
Adverse effects | No. of patients with initial Cmin | P-value | No. of patients with maximal Cmin | P-value | ||
|---|---|---|---|---|---|---|
< 20 μg/mL (n = 245) | ≥20 μg/mL (n = 267) | < 20 μg/mL (n = 235) | ≥20 μg/mL (n = 277) | |||
Nephrotoxicity on the 4th day | 7 (2.9%) | 9 (3.4%) | 0.739 | 7 (3.0%) | 9 (3.2%) | 0.861 |
Nephrotoxicity at the end of therapy | 19 (7.8%) | 21 (7.9%) | 0.963 | 17 (7.2%) | 23 (8.3%) | 0.653 |
Hepatotoxicity on the 4th day | 4 (1.6%) | 4 (1.5%) | 1.000 | 4 (1.7%) | 4 (1.4%) | 1.000 |
Hepatotoxicity at the end of therapy | 7 (2.9%) | 4 (1.5%) | 0.366 | 7 (3.0%) | 4 (1.4%) | 0.360 |